Article number reates to Ethical Rules of the Pharmaceutical Industry (LER) (Chapter 2, section 3)

						т	EMPLATE							
												Date of publication:	31May2017	
	Full name	HCPs: City of Principal Practice HCOs: city of practice (registered address)	Country of principal practice	Principal practice address (e.g. clinic/office/ healthcare unit/department)	Unique identifyer - OPTIONAL	Donations to HCOs (article 9)	Contribution to costs of events (article 9)			Fee for service and consultancy (article 9)			TOTAL OPTIONAL	
	(article 2)	(article 9)	(article 1)	(article 9)	(article 9)		Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an event	Registration fees	Travel and accomodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel and accomodation			
Ps	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be availabe for the individual Recipient or public authorities' consultation only, as appropriate.													
	Martin Lagging		Sweden			E/T	E/T			10000			10000	
	Zandra Nyman	Piteå	Sweden			E/T	E/T			3000			3000	
HCPs		OTHER, not included above - where information cannot be disclosed on an individual basis with regard to the Swedish Data Protection Act (PUL) (1998:204)												
	Aggregate amount attributable to transfers of value to such Recipients - article 10					N/A	N/A	Aggregate	Aggregate	Aggregate	Aggregate			
	Number of Recipients					N/A	N/A	number	number	number	number			
	% of total number of recipients of individual HCPs					N/A	N/A	%	%	%	%		N/A	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
	Pax Fungi AB	Piteå	Sweden					E/T	E/T	25000	5000		30000	
HCOS	OTHER, not included above - where information cannot be disclosed per HCO for legal reasons													
т	Aggregate amount attributable to transfers of value to such Recipients - article 10					Aggregate	Aggregate	N/A	N/A	Aggregate	Aggregate			
	Number of Recipients					number	number	N/A	N/A	number	number			
	% of total number of recipients of individual HCOs - article 10					%	%	N/A	N/A	%	%	1	N/A	
	Not: N/A = Not						1				1	ļ		
	Applicable AGGREGATE DISCLOSURE													
R&D	Transfers of value re Research & Development (as defined) (article 12 and article 1)											277394		